Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $16.42 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
Fennec Pharmaceuticals Stock Down 5.7 %
Shares of NASDAQ FENC traded down $0.37 during trading on Thursday, hitting $6.13. 603,592 shares of the company traded hands, compared to its average volume of 113,443. The company has a 50-day moving average price of $6.39 and a 200-day moving average price of $5.63. The firm has a market capitalization of $168.96 million, a P/E ratio of -61.29 and a beta of 0.36. Fennec Pharmaceuticals has a 1 year low of $3.96 and a 1 year high of $11.49.
Insider Buying and Selling
In related news, Director Rosty Raykov sold 10,000 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total value of $66,600.00. Following the completion of the sale, the director now owns 76,294 shares of the company's stock, valued at $508,118.04. This represents a 11.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 31,186 shares of company stock worth $203,389 in the last three months. 10.98% of the stock is owned by insiders.
Wall Street Analyst Weigh In
FENC has been the subject of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday. Wedbush reissued an "outperform" rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a research report on Monday. Finally, Stephens raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
Get Our Latest Stock Report on Fennec Pharmaceuticals
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
